Pilot Therapeutics
This article was originally published in The Tan Sheet
Executive Summary
Company retains Quintiles (Research Triangle Park, N.C.) to conduct a randomized, double-blind, placebo-controlled clinical study of Pilot's dietary supplement for asthmatics beginning in the fourth quarter. Resulting data will include information from a rising-dose tolerance study. Winston-Salem, N.C.-based Pilot plans to market the product as inhibiting the production of leukotrienes, which are asthma biomarkers. The supplement contains gammalinolenic acid and a delta-5 desaturase inhibitor (1"The Tan Sheet" July 10, p. 8)